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1. Introduction 
Glioblastoma multiforme (GBM, World Health Organization grade IV glioma) is the most 
common and aggressive form of brain cancer in adults and accounts for 17% of all 
childhood cancers (Cheng et al., 2010; Dirks, 2008). Even with conventional cancer 
treatment, the median survival time is between 12-15 months, with a 2-year median survival 
rate between 8% and 12% (Stupp et al., 2002; Stupp et al., 2005). This grim prognosis is 
partly due to GBM cells infiltrating the brain and spinal cord thus preventing complete 
surgical resection. These invasive tumour cells appear to be more resistant to cytotoxic 
therapy and have a higher proliferative potential (Furnari et al., 2007). Additionally, 
molecular profiling of GBMs have indicated that there is great heterogeneity within these 
tumours which may be due to the presence of a sparse population of cancer cells that exhibit 
stem-cell-like characteristics (Mischel et al., 2003; Parsons et al., 2008; Paugh et al., 2010; 
Verhaak et al., 2010). Specifically, these cells are able to self-renew and retain the capacity to 
differentiate but lack proliferative control. These stem-like cancer cells are referred to as 
either tumour-initiating cells or cancer stem cells (CSCs), and have been identified in a 
number of hematopoietic malignancies and solid tumours (Hope et al., 2004; C. Li et al., 
2007; Ricci-Vitiani et al., 2007; Singh et al., 2004; Stingl & Caldas, 2007). CSCs have also been 
shown to be more resistant to conventional cancer drugs and have been implicated in the 
more aggressive nature of tumour drug resistance after remission (Bao et al., 2006; Dean et 
al., 2005). Hence, by effectively targeting these CSCs the prognostic outcome of GBM 
patients may be improved. However, the development of novel oncolytic therapeutics to 
target CSCs is currently hindered by the scarcity of CSCs found within these solid 
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tumours. Thereby, the development of novel drug treatments may rely on a continuous 
and reproducible supply of tissue for genomic analysis and high-throughput drug 
screening. 
In order to address this issue, there is a major need for a large-scale cell expansion platform 
that allows for the generation of a large number of GBM-derived tissue containing cancer 
stem cells (GBM-CSCs). It has been shown that neurosphere culture can isolate and enrich 
GBM-CSCs (Singh et al., 2003; Yuan et al., 2004). There has been some controversy with this 
method of derivation, and recently data was presented by Dirks and colleagues who argued 
that GBM cell populations expanded in adherent culture, in comparison to neurosphere 
culture, have uniform access to growth factors and that adherent culture hampers the ability 
of short-lived progenitor cells to proliferate (Pollard et al., 2009). By comparing expression 
of differentiation markers on glioma cells grown in both adherent and sphere-forming 
culture, they found that increased numbers of cells grown as spheres expressed these 
differentiation markers. However, a source of contention is that the authors only compared 
one type of serum-free medium for the expansion of these glioma cells as spheres and also 
grew them in static vessels where the cells did not experience any shear forces. In a 
contrasting study, De Witt Hammer et al. (2008) showed that the genomic profiles of GBM-
derived cells grown in spheroid culture were more representative of the parental tumor 
profiles, whereas in adherent cultures, genetic changes developed that led to genetic 
deviations from the parental tumors. Based on our studies with neural precursor cells from 
multiple regions of the brain and with GBM-derived CSC tissue, we have shown that we can 
expand these cells reproducibly in suspension culture (Baghbaderani et al., 2008; 
Baghbaderani et al., 2010; Panchalingam et al., 2010). Additionally, we have shown that 
the bioreactor-expansion of GBM-derived CSC tissue as spheroids conserves the basic 
nature of the tissue (Panchalingam et al., 2000). This was achieved by using a serum-free 
medium, PPRF-h2, which was developed in our laboratory for neural cell isolation and 
expansion.  
Typically, GBM-CSCs are expanded in static culture vessels prior to use in basic cancer 
research. However, these conventional culture systems for expanding GBM-CSCs are 
inefficient at generating large numbers of cells and are labour intensive and non-
homogenous. Therefore, we looked to develop protocols using suspension bioreactors 
which can lead to better process control. Shear fields in our suspension bioreactors were 
controlled with a central impeller that was able to eliminate concentration heterogeneities 
and lead to homogenous environmental conditions. Moreover, the shear generated by the 
impeller influenced tissue aggregate size, therefore allowing for the expansion of the 
generation of homogenous GBM-CSC spheroids. We adapted large-scale suspension 
bioreactor culture protocols for the expansion of human neural precursor cells to human 
GBM-derived CSC tissue. Studies were conducted to investigate the role of different 
bioengineering parameters on the expansion of GBM-derived CSC tissue. Through the 
refinement of experimental procedures, we were able to expand successfully our cell 
populations. Additionally, we were able to show that these bioreactor-expanded GBM-
derived CSC tissue retained similar genetic characteristics to the initial cell population 
(Panchalingam et al., 2010). Through the use of a serum-free medium, PPRF-h2 
(Baghbaderani et al., 2010), and the development of successful bioprocess cell expansion 
conditions, we can alleviate the bottleneck in GBM-CSC supply for use in research and 
potentially for the development of new brain cancer therapies through small molecule 
screening. 
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2. Human glioblastoma multiforme (hGBM) 
Brain tumours are the leading cause of death resulting from solid cancers in children under 
the age of 20, and the third leading cause of death in young adults age 20-39 (Jemal et al., 
2007). Moreover, brain tumours are diversely defined based on their histological 
characteristic and tissue origin (Vescovi et al., 2006). In general, brain tumours arise from 
brain cells (primary brain tumours) or from metastatic tumours originating from other areas 
of the body (secondary brain tumours) which continue to proliferate in the brain. As the 
cancer cells proliferate and invade surrounding brain tissue, symptoms may result including 
hemiparesis, aphasia, and seizures. Additionally, as the tumour grows intracranial pressure 
also increases due to the space constraints in the skull. The increase in pressure causes 
secondary complications by damaging or killing healthy brain cells, resulting in symptoms 
such as headaches, nausea, and changes in mental status (Patkar et al., 2000).  
Astrocytic tumours, the most common type of gliomas, are typically classified based on their 
histological features and fall into two categories: low-grade or high-grade tumours. Low-
grade astrocytic tumours (World Health Organization (WHO) Grade I and II) such as 
pilocytic astrocytomas, have an appearance similar to normal cells and tend to grow slowly. 
High-grade astrocytic tumours (WHO Grade III and IV), are tumours that tend to grow 
quickly, invade nearby tissue and the tumour cells have a different appearance than normal 
cells. GBMs are classified as grade IV astrocytic tumours (Siebzehnrubl et al., 2011). 
Histopathological features of GBMs usually include cellular anaplasia (undifferentiated cell 
growth), nuclear atypia, increased mitotic activity, vascular proliferation and extensive 
necrosis. Additionally, GBMs can arise as primary tumours or from the transformation of 
lower grade tumours into secondary tumours (Denysenko et al., 2010). Risk factors for 
gliomas remain elusive, although there have been some factors such as occupation, 
environmental carcinogens and diet which has been reported to be associated with the 
development of gliomas (Verma, 2009). 
The majority of brain tumours are diagnosed usually when the patient experiences seizures 
or neurological symptoms (such as cognitive or motor deficits) without a clear cause 
(DeAngelis, 2001). Currently, there is no method that has been developed for screening or 
preventing brain cancer. Upon diagnosis, the treatments for brain tumours are multimodal 
involving surgical resection, radiation and chemotherapy. In children younger than three 
years of age, it is standard practice to employ chemotherapy instead of radiation due to its 
negative effect on the developing nervous system (Pollack, 1994). However, in both children 
and adults, these treatment modalities are not curative and invariably result in relapse and 
treatment failure. Also, since these treatments are invasive in nature, they usually result in 
cognitive impairment among other side-effects (Taphoorn & Klein, 2004). Due to the lack of 
effective therapeutic options, the effective treatment of GBMs represents a major challenge 
to clinicians.  
3. Cancer stem cells 
3.1 Cancer stem cell hypothesis 
The cancer stem cell hypothesis proposes that tumours arise from stem cell-like tumour-
initiating cells (TICs) or cancer stem cells (CSCs), capable of self-renewal but lacking 
proliferative control, which are the instigators of tumour formation and the precursors of 
malignancy (Reya et al., 2001; Singh et al., 2004). Under normal physiological conditions, 
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stem cells would either self-renew or differentiate into proliferating progenitor cells. These 
proliferating progenitor cells would then be able to differentiate and give rise to the cell 
populations of that tissue type (i.e. oligodendrocytes, neurons, or astrocytes) [Figure 1]. 
According to the cancer stem cell hypothesis, a mutagenic agent (e.g. environmental 
stresses) would cause the oncogenic transformation of the stem cell or a down-stream 
progenitor cell. These transformed cancer stem cells would retain some stem cell properties, 
such as self-renewal, but uncontrollably produce differentiated non-tumourigenic cells that 
would form the bulk of the tumour. This hypothesis has lead to the identification of CSCs in 
numerous malignancies, including leukemia, breast cancer, brain cancer, pancreatic cancer, 
and colon cancer (Hope et al., 2004; C. Li et al., 2007; Ricci-Vitiani et al., 2007; Singh et al., 
2004; Stingl & Caldas, 2007). 
 
 
Fig. 1. Proposed mechanism of tumourigenesis through the formation of CSCs. Stem cells 
are able to self-renew and produce more differentiated progenies. Due to their long-lived, 
slow-dividing nature, they are exposed to damaging environmental factors over long 
periods of time, that may lead to the development of oncogenic mutations. The result of 
these mutations give rise to CSCs (also known as tumour-initiating cells). It has also been 
hypothesized that CSCs can be formed from the dedifferentiation of committed cells which 
also acquire oncogenic mutations. These CSCs uncontrollably produce large quantities of 
non-tumourigenic cells that result in a tumour mass 
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3.2 Alternate view of the cancer stem cell hypothesis 
Quintana et al. (2008) questioned the existence of CSCs within human melanomas. The 
authors argued that the original assessment of the scarcity of CSCs in human high-grade 
melanoma (0.001%), was an artefact of a xenotransplant tumour-initiation assay, caused by 
residual innate immunity of the recipient mouse. Dissociated melanoma cells were 
transplanted in non-obese diabetic/severe compromised immunodeficient (NOD/SCID) 
mice at dilutions of 102-107, and found that only four of the seven samples generated 
palpable tumours after 8 weeks. Performing a limiting dilution assay, only 1 in 106 cells 
were observed to be tumour-initiating cells. However, by increasing the observation time to 
32 weeks, the CSC frequency increased to 1 in 105 cells (Quintana et al., 2008). Because 
NOD/SCID mice retain some innate immunity, Quintana et al. (2008), utilized a mouse 
model depleted of natural killer cells (NOD/SCID/Il2rg-/-). By utilizing this model along 
with Matrigel to provide the cells with a more supportive environment, it was found that 
15-25% of the tumour cells exhibited CSC activity, thereby creating uncertainty on the 
existence of a cancer cell hierarchy within human high-grade melanomas (Quintana et al., 
2008). The results of this study show that within human melanomas, CSCs might not be as 
scarce as once thought. However, these results cannot be directly correlated with other solid 
tumours in the body, since even in mouse models of leukemia there exists wide variations in 
the frequency of CSCs from higher than 1 in 106 cells (c-myc and bcr/abl/CDKN2) to 1 in 104 
cells (MOZ-TIF and Pten-/-) (Dick, 2009). From the results presented by Quintana et al. 
(2008), inferences may be made concerning the population of cancer stem cells within solid 
tumours. First, there may be human cancers that have a high-frequency of cancer stem cells 
that do not follow the cell hierarchy model (Eaves, 2008). Second, the optimization of assays, 
specifically xenotransplant models devoid of immunity, to correctly identify tumour cells 
that possess any stem cell function need to be further investigated. Third, it is important to 
develop tumour endpoints to discriminate between CSCs (or progenitors) that have limited 
self-renewal capacity and CSCs that possess extensive capacity for self-renewal (Dick, 2009). 
3.3 Brain cancer stem cells 
Brain tumours are phenotypically and morphologically diverse. Additionally, the tumours 
mass is highly heterogeneous and the CSC hypothesis reasons that this observed 
heterogeneity is due to the existence of a hierarchical organization, in which CSCs are the 
parental cell for the other cells present in the tumour (Siebzehnrubl et al., 2011). 
Consequently, the development of an assay that identifies the cells responsible for 
maintaining tumour growth may lead to the development of novel effective therapies to 
treat brain tumours. Also, Singh et al. (2003) showed that human brain cancer cells 
expressing the surface marker CD133 are capable of tumourigenesis in NOD/SCID mice 
with as few as 100 cells, whereas the brain cancer cells lacking this expression appear to 
have no proliferative ability. In addition, they obtained human brain tumours and 
enzymatically dissociated them to generate a single cell suspension. The cells were 
inoculated into conditions shown to be conducive for the isolation of neural stem cells. In 
culture, a minority of the cells formed neurosphere-like clusters (termed tumourspheres), 
which showed immunoreactivity for Nestin (a marker of neural stem cells) and CD133 (a 
putative marker of neural stem cells) (Singh et al., 2003). A sphere formation assay was 
carried out to assess the frequency of the stem cell population which yielded a frequency 
between 0.3% to 25.1%. They demonstrated that the CD133+ population of cells differentiated 
in culture into tumour cells that phenotypically resembled the tumour from the patient 
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(Singh et al., 2003). However, not every CD133+ brain cancer cell was able to form spheres in 
vitro, indicating that the CD133+ brain cancer cells contain a subpopulation that are the 'true' 
brain cancer stem cells (Singh et al., 2003; Ward & Dirks, 2007).  
In 2004, Galli and colleagues (Galli et al., 2004) isolated tumourigenic brain cancer cells from 
human GBMs that exhibited characteristics consistent with neural stem cells. The cells were 
found to be unipotent in vivo and multipotent in vitro, which may have resulted from the 
influence of the microenvironment on cellular signaling. Also, the cells were capable of 
generating tumours, through serial transplantations, that had similar histopathological 
features as the original tumour. As the cells were grown in vitro, the growth rate of the cells 
increased for the later passages, which could be attributed to an increase in the amount of 
proliferative cells. Interestingly, although all the cell lines studied were identified 
histopathologically as GBMs, they displayed varying growth kinetics and differentiation 
profiles. As stated previously, histopathological diagnosis of brain tumours is very 
subjective and may be unable to identify tumour variability between patients. This study 
suggests that the variability seen between GBM-cell lines might explain the differential 
response of tumour patients to treatment modalities (Galli et al., 2004).  
Since the seminal paper by Singh et al. (2004), it has been shown by multiple groups, that 
CD133 is not a definitive CSC marker (Beier et al., 2007; Joo et al., 2008). Not only do 
CD133+ cells form tumours in an immunodeficient animal model, but also CD133- cells 
have been shown to form tumours. From this, many new markers for CSCs have been 
proposed such as stage-specific embryonic antigen 1 (SSEA-1), A2B5, SRY-like high mobility 
group 2 (Sox2), Sox4 and many others (Fang et al., 2011; Phi et al., 2008; Son et al., 2009; 
Tchoghandjian et al., 2010).  
3.4 Therapeutic implications of the cancer stem cell hypothesis 
Ideally, untransformed adult stem cells should remain functional throughout an individual's 
lifetime and retain the capacity to produce large quantities of undifferentiated progeny. In 
order to preserve this ability, stem cells have developed mechanisms to protect themselves 
from external factors that may potentially have an adverse effect on their function. 
Specifically, one such mechanism is the activation of ATP binding cassette (ABC) 
transporters, which are integral to DNA repair and inhibit apoptosis (Dean et al., 2005; S. 
Zhou et al., 2001).  
It has been suggested that CSCs can develop from either stem cells or progenitor cells, or 
dedifferentiate from somatic differentiated cells, upon mutation of cancer-critical genes (B. 
B. Zhou et al., 2009). If CSCs are derived from stem/progenitor cells, it has been suggested 
that they would acquire the drug resistance mechanisms found in stem/progenitor cells. In 
GBMs this may explain the drug resistance observed for these tumours, as well as the high 
probability of recurrence. Four viewpoints have been developed on the implications of this 
drug resistance: 
• CSCs, through their derivation from normal adult stem cells, acquire natural drug 
resistance thereby aiding their survival during chemotherapy, and preventing their full 
elimination from the body (Dean et al., 2005).  
• Upon chemotherapy, some cancer cells acquire drug resistance that permits their 
survival. Following chemotherapy, the surviving cells pass on their drug resistance to 
their progeny, thereby rendering the original treatment of limited value (Dean et al., 
2005).  
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• Chemotherapy selects for drug-resistant CSC variants that then repopulate the tumour 
with progenies that are also drug-resistant after chemotherapy (Dean et al., 2005).  
• CSCs and their resulting progenies are inherently drug-resistant and therefore therapies 
have little or no effect on the tumour (Dean et al., 2005). 
Presently, it is not clear which viewpoint represents the correct tumour model. However 
with the discovery of CSCs and their role in the formation of tumour drug-resistance, it is 
clear that the development of effective cancer therapeutics must be focused on this cell 
population. The use of surgery, radiation therapy and chemotherapy are not only invasive 
and ineffective, but are also standardized for the histopathology of the tumour without 
regards to its molecular basis. Hence, a systems biology approach to analyze in vitro 
expanded CSCs within hGBMs can lead to the development of oncolytic drugs that 
specifically target the molecular pathways within the GBM-CSC population (Foltz et al., 
2006; Foltz et al., 2009; Shah et al., 2011; Yan et al., 2011). In order to generate a clinically-
relevant number of patient-specific GBM-CSCs, it is necessary to optimize the in vitro 
culture environment, such that the basic genetic nature of the GBM-CSCs does not 
significantly change.  
4. Culture conditions 
Initially, GBM-derived CSCs were isolated and expanded in neurosphere culture based on 
protocols developed for the isolation and expansion of murine and human neural precursor 
cells (NPCs). However, a recent publication evaluated the derivation and expansion of 
GBM-derived CSC-lines in adherent culture. In this section both neurosphere and adherent 
culture will be discussed and evaluated.  
4.1 Neurosphere cultures 
In a landmark paper, Reynolds and Weiss (Reynolds & Weiss, 1992) were the first 
researchers to isolate neural stem cells (herein referred to as neural precursor cells (NPCs)) 
from the adult mouse brain using the neurosphere formation assay. They generated a single 
cell suspension of cells from the striatial tissue (including the subventricular zone), and 
inoculated this cell suspension into culture dishes void of attachment substrates. In these 
conditions, free floating spheres (termed neurospheres) formed from NPCs present in the 
murine brain. This was confirmed by analyzing the cells for defining stem cell 
characteristics, namely (1) self-renewal, and (2) differentiation into astrocytes and neurons 
(unipotent). Their methods were adapted over the years by key research groups for the 
isolation and expansion of human NPCs and GBM-derived CSC lines (Baghbaderani et al., 
2008; Baghbaderani et al., 2010; Galli et al., 2004; Kelly et al., 2009; Panchalingam et al., 2010; 
Singh et al., 2003; Svendsen et al., 1998; Vescovi et al., 1999). 
Conventionally, GBM-derived CSC lines are derived from a single cell suspension of 
dissociated GBM-derived cells inoculated into suspension conditions (either ultra-low 
attachment vessels or uncoated tissue culture vessels), and allowed to expand as 
neurospheres in serum-free culture medium. GBM-derived neurospheres are heterogeneous 
by nature and contain both stem and progenitor cells. However, it has been shown that the 
genomic changes in GBM cells expanded as neurospheres resemble the same changes 
detected in the primary tumours of the corresponding patients (Ernst et al., 2009). 
Additionally, in contrast to adherent culture, cells in neurosphere cultures maintain these 
genomics over the culture period (De Witt Hamer et al., 2008).  
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4.2 Adherent cultures 
Recently, Dirks and colleagues (2009) reported on work which involved modifying the 
original protocol by Reynolds and Weiss (1992), by adding laminin as an attachment factor 
and culturing the cells as a monolayer of adherent cells. The authors expanded GBM-
derived CSC lines in adherent and neurosphere culture and showed the cells in 
neurospheres expressed higher levels of differentiation markers. Also, higher levels of cell 
death were found within the neurospheres (Pollard et al., 2009). Using copy-number gains 
on the chromosomes and differentiation propensity, Pollard et al. (2009) showed that 
differentiated adherent cells were similar to parental tumours and that the adherent cells 
exhibited genomic characteristics commonly associated with glioblastomas. However, as 
mentioned in the previous section, there have been many groups that have shown that cells 
expanded in neurosphere culture exhibit similar genomics as seen in the parental tumour. 
Pollard et al. (2009) also did not mention the size of spheres that were analyzed. It is critical 
to consider the size of spheres in culture since mass transfer limitations in large spheres can 
result in the formation of necrotic centers (due to an inadequate supply of oxygen and 
nutrients to cells in the center of the spheres). This could have biased their comparison of 
neurospheres and adherent cells [for a comprehensive review please refer to Reynolds and 
Vescovi (2009)]. Based on our extensive work with neurosphere culture, and the work that 
has been done by numerous other groups, we chose to isolate and expand our GBM-derived 
CSC lines as neurospheres. 
5. Development of PPRF-h2 medium 
PPRF-h2 medium was developed to support the long-term expansion of human NPCs 
(hNPCs) in culture while retaining the multipotency of the cells (Baghbaderani et al., 2010). 
This medium was developed from an existing medium utilized for the expansion of murine 
NPCs (mNPCs) called PPRF-m4 (Sen et al., 2001). Modifications to this pre-existing medium 
focused on the dose-dependent effect of basic fibroblast growth factor (bFGF) and human 
leukemia inhibitory factor (hLIF) on the expansion and differentiation of hNPCs in culture. 
Additionally, the effect of dehydroepiandrosterone (DHEA) on the proliferation and 
differentiation of hNPCs was investigated. The different medium modifications studied are 






Growth supplements added to the base medium 
Control PPRF-m4 10 μg/L bFGF 
PPRF-h1 PPRF-m4 20 μg/L bFGF + 10 μg/L hLIF 
PPRF-h2 PPRF-m4 20 μg/L bFGF + 10 μg/L hLIF + 1.0 μM DHEA 
Table 1. The formulations of three different growth media that were developed by adding 
growth supplements (i.e. bFGF, hLIF and DHEA) to an existing serum-free medium (PPRF-
m4) (Baghbaderani et al., 2010). 
Fetal cortical-derived hNPCs were expanded in static suspension culture in the three 
different culture modifications outlined in Table 1. Cells expanded in PPRF-h2 resulted in a 
higher viable cells density over five passages. The cumulative cell-fold expansion over five 
passages in PPRF-h2 medium was 2.17±0.5x104, which was significantly higher than cells 
expanded in PPRF-h1 (0.59±0.1x104) or control medium (0.07±0.03x104) [Figure 2A and 2B] 
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(Baghbaderani et al., 2010). Cells in PPRF-h2 and PPRF-h1 medium also formed larger 
aggregates (approximately 500 μm). The aggregates were morphologically different 
compared to aggregates expanded in PPRF-m4 medium [Figure 2C] (Baghbaderani et al., 
2010) which adhered to the surface of the culture flask. This altered the phenotype of the 
cells as differentiation analysis showed a significantly higher number of neurons were 
derived from hNPCs expanded in PPRF-h2 medium (43.6±2%) compared to the control - 
PPRF-m4 medium (22.9±2%) (Baghbaderani et al., 2010). 
 
 
Fig. 2. Stationary culture of fetal cortex-derived hNPCs in three different growth medium: 
control medium, PPRF-h1 and PPRF-h2. Shown are (A) viable cell density and viability and, 
(B) overall cell-fold expansion of hNPCs from P10 to P14 over 70 days in the three different 
growth media. Also shown are photomicrographs of cells grown in (C) control medium,  
(D) PPRF-h1 medium and (E) PPRF-h2 medium at 14 days post-inoculation (P14). The inset 
shows a higher magnification of the aggregates (shown by arrow) adhered to the surface of 
the culture flask in the control medium. Scale bars represent 500 μm (scale bar in the inset is 
250 μm) (Baghbaderani et al., 2010) 
Since the presence of bFGF and hLIF in the growth medium exhibited a potent effect on the 
expansion and differentiation of hNPCs, the dose-dependent effect of bFGF and hLIF on the 
expansion of hNPCs was also investigated. Levels of bFGF were varied between 0-40 μg/L 
in PPRF-h2 medium. While there was a dose-dependent effect of bFGF on the proliferation 
of hNPCs (i.e. cell-fold expansion of hNPCs increased with increasing levels of bFGF), the 
addition of bFGF above 20 μg/L did not provide any significant beneficial effect on the 
www.intechopen.com
 Cancer Stem Cells - The Cutting Edge 
 
484 
proliferation of hNPCs (Baghbaderani et al., 2010). Additionally, hLIF was varied between 
0-20 μg/L. We observed that above 10 μg/L that there was no added beneficial effect on the 
growth of the hNPCs (Baghbaderani et al., 2010). Based on this study, a final concentration 
of bFGF and hLIF in PPRF-h2 medium was maintained at 20 μg/L and 10 μg/L, respectively 
(Baghbaderani et al., 2010). 
6. Large-scale production of human glioblastoma-derived cancer stem cell 
tissue 
The development of therapies to target CSCs is hindered by the scarcity of the CSCs within 
solid tumours. In brain cancers, the frequency of cells expressing CD133 varied with 
pathological subtype and grade from 1% to as high as 45% (Joo et al., 2008). As discussed 
previously, not every CD133+ cell is capable of forming a sphere in vitro (an assay for CSC 
identification), and therefore a subpopulation within the CD133+ exists that contains the 
scarce 'true' CSCs or TICs (Ward & Dirks, 2007). It is this lack of pure populations of CSCs 
for research that hinders the development of effective cancer therapies. In developing 
effective cancer therapeutics, it will be necessary to observe and quantify the interactions 
within brain tumours which require drug regimes and therapeutics to be individually 
tailored. This would require a large number of cells obtained from each individual, so that 
numerous treatment modalities could be tested on it. The availability of CSCs in vivo limits 
the type of analyses that can be performed, restricts the knowledge that can be gained about 
the basic cancer stem cell biology and hinders the development of effective, individualized 
cancer therapeutics. Thus it is necessary to develop a bioprocess that is capable of producing 
a reproducible, clinically-relevant number of cells. 
Conventionally, the in vitro expansion of stem/progenitor cells has been performed in 
stationary tissue culture flasks. Although large cell numbers could be produced using this 
method of culture, it becomes increasingly laborious as the number of tissue culture flasks 
increases. Additionally, with handling a large number of tissue culture flasks, the 
probability of introducing cell culture variability between flasks becomes high, thereby 
reducing reproducibility between cultures. Such issues would be detrimental to the 
development of therapeutics since this culture variability would lead to increased 
phenotypic variability in cells expanded in different flasks, thereby impairing subsequent 
analysis to determine therapeutic targets. In order to generate large numbers of stem cells 
reproducibly, suspension bioreactors have been used for the expansion of a number of adult 
stem cell/progenitor lines. Figure 3 shows a comparison of the large-scale production of 
CSCs using tissue culture flasks and suspension bioreactors. A 1.0 L suspension bioreactor, 
for example, is equivalent to 200 T-25 tissue culture flasks using a 5.0 mL volume. The use of 
suspension bioreactors can generate a reproducible, large number of cells with well defined 
characteristics, while enabling control and maintenance of a homogenous environment. 
Suspension bioreactors to expand a population of adult and embryonic precursor cells have 
been discussed in detail in literature. We have expanded human and murine neural 
precursor cells, murine mammary epithelial stem cells and breast cancer stem cells as 
aggregates in suspension culture (Baghbaderani et al., 2008; Baghbaderani et al., 2010; Youn 
et al., 2006; Youn et al., 2005). We have shown that protocols developed for these cell types 
can be adapted to other cell types, such as hGBM-derived CSC tissue. hNPCs bioreactor 
expansion protocols were adapted for the expansion of hGBM-derived CSC tissue 
(Panchalingam et al., 2010). Baghbaderani et al. (2008) found that inoculating hNPCs at 
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1.0x105 cells/mL was conducive for cell growth. Operating in a semi-fed-batch mode 
resulted in a maximum cell density of 3.0x106 cells/mL over 18 days, corresponding to a 36-
fold expansion (Baghbaderani et al., 2008). From these protocols, we investigated the effect 
of key culture parameters on the proliferation and phenotype of hGBM-derived CSC tissue 
expanded in suspension bioreactors. These key bioengineering parameters were: (1) liquid 






Fig. 3. Comparison of large-scale CSC cultures using tissue culture flasks and bioreactors. 
Two methods of scale-up to larger volumes are available: (a) large number of T-flasks, and 
(b) a single bioreactor. Bioreactors are a significantly better alternative for anchorage 
independent cells due to their reproducible, homogeneous, controllable environment 
6.1 Bioengineering issues 
6.1.1 Bioreactor liquid shear 
Within suspension bioreactors, liquid shear control ensures adequate oxygen mass transfer 
and bulk fluid mixing. However, it is also important to make sure that hydrodynamic shear 
associated with the level of turbulence is within acceptable limits. The shear that is seen in 
stirred suspension bioreactors can have a negative impact on shear sensitive mammalian 
cells, but can also maintain aggregate size within acceptable limits (Kallos & Behie, 1999; 
Kallos et al., 1999; Sen et al., 2001). Also, the maximum shear stress occurs near the tip of the 
impeller, where turbulence is at its greatest (Cherry & Kwon, 1990). Briefly, Cherry and 
Kwon (1990) developed a relationship for maximum shear stress that is experienced by a cell 
on the surface of an aggregate. This relationship is represented by: 
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 ( ) 21
max
33.5 ενρτ =  (1) 
where τmax is the maximum shear stress (Pa), ρ is the medium density (kg/m3), and ν is the 
kinematic viscosity (m2/s). The power dissipation per unit mass, ε, can be calculated using 
the vessel working volume (V, m3) and density: 
 
ρε V
P=  (2) 
where P is the power input to the system (W), which is estimated by the Nagata (1975) 
correlation using the power number (Np). Since the power number is correlated with 
Reynolds number (and therefore with agitation rate), shear stress can be controlled by 
adjusting the agitation rate of the culture vessel. For hNPCs, we found that a maximum 
shear stress between 0.35 to 0.80 Pa may sustain the expansion of these cells in small-scale 
suspension culture (Baghbaderani et al., 2008). Within our 125 mL suspension bioreactors 
this corresponds to an agitation speed of 70 - 130 rpm. 
We inoculated hGBM-derived CSC tissue at 7.5x104 cells/mL and operated at either low 
shear (60 rpm) or high shear (100 rpm) in 125 mL suspension bioreactors under batch 
conditions and grown as neurospheres. hGBM-derived CSC tissue inoculated in high-shear 
conditions reached a maximum cell density of 9.30x105 cells/mL compared to cells 
inoculated in low-shear conditions which reached a maximum cell density of 6.15x105 
cells/mL (p-value = 0.046). This corresponded with a cell-fold expansion of 14.4 and 7.0 for 
the high- and low-shear condition, respectively. Moreover, we observed that the mean 
neurosphere diameter on day 22 was around 300 μm for the low-shear condition. Whereas, 
in the high-shear condition the mean neurosphere diameter did not exceed 200 μm. Over the 
entire course of the study, the average neurosphere size in the low-shear condition was 
higher than for the cells expanded in the high-shear condition. Additionally, the standard 
deviation of the diameters of neurospheres expanded in the high-shear condition was lower 
than the neurospheres expanded in the high-shear condition. This implies our high-shear 
expansion of hGBM-derived CSC tissue can lead to more homogenous culture morphology. 
6.1.2 Inoculation density 
Inoculation density is an important parameter in cell culture. Inoculating at too low a cell 
density may not be sufficient to support cell growth or cause a considerably prolonged lag 
phase. Such a low cell density will lead to a lack of cell-to-cell contact, which has been 
shown to be crucial to initiate cell expansion. Moreover, the release of autocrine factors 
released by the cells inoculated at a low density may not be sufficient for cell growth. In 
contrast, inoculating the cells at too high a cell density can result in (1) a lower cell-fold 
expansion and, (2) the need to sparge oxygen into the culture in order to maintain adequate 
oxygen transfer. To successfully grow hNPCs a sufficiently high inoculation density was 
required for their expansion (1.0x105 cells/mL) (Baghbaderani et al., 2008). Additionally, 
preliminary experiments on the expansion of hGBM-derived CSC tissue in static suspension 
culture experiments found that inoculating hGBM-derived CSC tissue at 5.0x104 cells/mL 
resulted in the highest cell-fold expansion (Baghbaderani et al., 2008). We further 
investigated the influence of inoculation density on the expansion of hGBM-derived CSC 
tissue in our 125 mL stirred suspension bioreactors. Cells were inoculated at a density of 
5.0x104 cells/mL and 1.0x105 cells/mL. An inoculation density of 5.0x104 cells/mL resulted 
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in the highest cell fold expansion (19.9) with the cells attaining a maximum viable cell 
density of 1.12x106 cells/mL. Additionally, we observed that at the higher cell density, that 
the consumption of key nutrients, namely glutamine and glucose, was higher compared to 
the cells inoculated at the lower cell density. Additionally, the nutrient uptake of bioreactor-
expanded hGBM-derived CSC tissue to hNPCs, was higher, even when comparing hNPCs 
inoculated at 1.0x105 cells/mL (compared to 5.0x104 cells/mL for hGBM-derived CSC 
tissue). The rapid loss of nutrients from the culture medium may be mitigated by using a 
semi-fed-batch approach. 
6.1.3 Feeding strategy 
As cells proliferate in culture, they metabolize key nutrients in the medium (i.e. glutamine 
and glucose) and produce toxic by-products (i.e. ammonium and lactate) (Butler, 2004). 
Within tumours, the rate of glycolysis and glutaminolysis are higher than their 
untransformed counterparts, and nutrient limitations have been shown to be an important 
factor on cancer tissue expansion (DeBerardinis et al., 2008; Elstrom et al., 2004; Youn et al., 
2006). The 'Warbug' effect states that in tumour cells the increased rate of glycolysis is 
accompanied with an increase in the lactate production of the tumour cells (Kim & Dang, 
2006; Vander Heiden et al., 2009). This contrasts with their untransformed counterparts 
which - (1) have comparatively low rates of glycolysis and, (2) metabolize glucose to 
pyruvate (part of aerobic respiration) within the mitochondria. This 'effect' is a metabolic 
hallmark of aggressive tumours, as the cells utilize anaerobic respiration in order to 
maintain their need for large amounts of energy. Additionally, within cell culture glutamine 
serves as not only an energy source for the cells, but also as a source of reduced nitrogen for 
maintenance of nucleotide biosynthesis and non-essential amino acids (Newsholme et al., 
2003). From this information and our previously discussed studies, it was surmised that 
periodic medium replacement within our stirred suspension bioreactor hGBM-derived CSC 
tissue cultures may be beneficial. Baghbaderani et al. (2008) replaced 40% of the culture 
medium every 6 days for the expansion of hNPCs in suspension bioreactors. However, 
hGBM-derived CSC tissues utilized their nutrients at a higher rate than hNPCs and also 
produce the associated metabolic by-products at a higher rate. Therefore, in our work we 
examined the effect that a 40% medium replacement every 6 days as well as every 2 days 
had on the expansion and phenotype of bioreactor-expanded cells. Total medium 
replacement was not considered, since it has been suggested that cells in culture secrete 
endogenous factors that support cell proliferation (Zandstra & Nagy, 2001). It was found 
that hGBM-derived CSC tissue expanded in 125 mL suspension bioreactors in a 2-day fed-
batch mode (40% medium replacement every 2 days) resulted in the highest expansion (90 
cell-fold expansion) [Figure 4] (Panchalingam et al., 2010). Additionally, it was seen that as 
the cultures progressed, significantly larger aggregates were seen in the 2-day fed-batch 
conditions, resulting in average aggregate sizes around 600 μm compared with 350 and 450 
μm in the batch and 6-day fed-batch conditions, respectively, on day 24. Baghbaderani et al. 
(2008) found that average aggregate diameters of < 600 μm would not compromise cell 
viability and would maintain the phenotypic characteristics of the hNPCs. Nutrient and 
metabolite analysis was performed for all the culture conditions, and it was observed that in 
the fed-batch conditions there was an increase in the specific consumption rate of glucose 
and glutamine. This resulted in an increase in the specific production rate of lactate and 
ammonium in the fed-batch culture conditions compared to the batch conditions. The level 
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of lactate and ammonium however did not rise above 2.0 g/L and 2.0 mM, which is 
generally considered detrimental for mammalian cell growth (Butler, 2004). The difference 
in nutrient uptake between batch and fed-batch conditions illustrates the activation of 
different metabolic pathways that may affect the phenotype bioreactor-expanded hGBM-
derived CSC tissue.  
 
 
Fig. 4. Viable cell density and percent viability of hGBM-derived CSC tissue grown in batch, 
6-day fed-batch, and 2-day fed-batch culture modes. All data points represent the average of 
duplicate bioreactors ± S.D. (Panchalingam et al., 2010) 
Cell phenotype was assessed by (1) using flow cytometry to quantify the expression of the 
surface antigen CD133, (2) differentiation analysis to observe the propensity of cells to 
differentiate into the three neural lineages and, (3) microarray analysis to identify whether 
the bioreactor expansion process changed the basic nature of the hGBM-derived CSC tissue. 
The hGBM-derived CSC tissue in the fed-batch conditions maintained their CD133 
expression greater than 90% for the entire course of the experiment. In comparison, cells 
expanded in the batch conditions had a CD133 expression of 95% on day 24 which 
decreased rapidly as cell viability decreased (Panchalingam et al., 2010). 
Immunocytochemical analysis of undifferentiated cells revealed that the hGBM-derived 
CSC tissue were positive for GFAP (GFAP+, a marker of astrocytes) and negative for Nestin 
(Nestin-, a marker of neural stem cells) (Panchalingam et al., 2010). It has been shown that 
GFAP+/Nestin- cells are a subset of cells derived from glial progenitor cells (Miyaguchi, 
1997). Upon differentiation, the cells spontaneously differentiated into primarily GFAP+/β-
tub+ (a marker of neurons) cells. Genomic analysis of the hGBM-derived bioreactor-
expanded CSC tissue revealed that there were more genomic changes within the 2-day fed-
batch condition compared to the batch condition. However, Gene Ontology (GO) 
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enrichment analysis revealed that key genomic constructs were less affected than in the 
other culture conditions [Figure 5]. These findings show that the bioreactor-expansion of our 
hGBM-derived CSC tissue using a 2-day fed-batch methodology results in cells maintaining 
their phenotypic and genomic characteristics.  
 
 
Fig. 5. Differentially-expressed genes of bioreactor-expanded GBM-derived CSC tissue grown 
in batch, 6-day-fed-batch and 2-day fed-batch culture modes. Shown are (A) the number of 
genes that showed a fold changed greater than 2 with a p-value < 0.007 and, (B) gene ontology 
(GO) annotations for the differentially-expressed genes with a p-value < 0.007 for the three 
different culture conditions on day 24 compared to day 0. Red represents above-average 
expression level, green represents below-average expression level, and black represents no 
change in the gene expression with cells before inoculation into the bioreactors 
(Panchalingam et al., 2010) 
6.1.3 Culture medium 
Within our laboratory, the influence of different culture components on the growth kinetics 
and phenotype of different stem/progenitor lines has been evaluated (Baghbaderani et al., 
2010; Jung et al., 2010). As was mentioned in previous sections, studies were done to 
elucidate the influence of bFGF, hLIF and DHEA on the proliferation and phenotype of 
hNPCs (Baghbaderani et al., 2010). We observed that these chemical mitogens had a 
significant effect on the growth kinetics and phenotype of hNPCs. Moreover, we evaluated 
the effect our growth medium, PPRF-h2, had on the growth kinetics of hGBM-derived CSC 
tissue in suspension culture compared to another growth medium used extensively by other 
research groups, Neurocult NSA (STEMCELL Technologies, Vancouver, Canada). Two 
glioma cell lines (SN184-grade II glioma-derived and SN143-hGBM-derived) were 
inoculated at 5.0x104 cells/mL into 125 mL stirred suspension bioreactors in either PPRF-h2 
or NSA medium. Here, the SN184 and SN143 cells in PPRF-h2 medium reached a maximum 
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viable cell density of 2.7x106 cells/mL and 3.4x106 cells/mL (80.6 and 73.2 cell-fold 
expansion), respectively. In NSA medium, the SN143 and SN184 cells reached a maximum 
viable cell density of 2.2x106 cells/mL and 3.1x106 cells/mL (data not shown). Also, we saw 
that the cells in both media had similar aggregate size distributions. Although the growth 
kinetics of the cells were similar in both media, it will be important to evaluate the genomics 
of the cells as they may have been altered through the culture period. This is currently being 
evaluated within our laboratory. 
6.1.4 Hypoxia 
The expansion of hNPC and GBM-derived CSC tissue in vitro has often been done at 
atmospheric oxygen levels of 21% (Baghbaderani et al., 2010; Panchalingam et al., 2010). 
However, the physiological levels of O2 in the brain vary between 2.5% to 12.5%, and in 
solid tumours it has been reported that the oxygen tension can be below 0.1% in necrotic 
regions (Bar, 2011; Panchision, 2009). hGBM tumours were shown to experience mild to 
moderate/severe hypoxia, with oxygen concentrations between 0.5% to 2.5% for mild 
hypoxia and 0.5% to 0.1% for moderate/severe hypoxia (Bar, 2011). This agrees with the 
observations by many researchers who note that hypoxia tends to correlate with increased 
tumour aggressiveness (Evans et al., 2004; Helczynska et al., 2003; Jogi et al., 2002; Kunz & 
Ibrahim, 2003). This may be due to the different genes that are upregulated in hypoxic 
conditions, which are primarily controlled by hypoxia-inducible factors 1α, 2α, and 3α (HIF-
1-3α) (Bar, 2011). HIF-1α has been shown to repress p53, which is a major effector of mitotic 
arrest and apoptosis and can also block normal CNS precursor differentiation (Gustafsson et 
al., 2005; Hammond & Giaccia, 2005; Panchision, 2009). Also, it has been shown that HIF-1α 
and HIF-2α can result in an increase in the expression of CD133 (Z. Li et al., 2009; Soeda et 
al., 2009). Expanding hGBM-derived CSC tissue in vitro under physiological oxygen 
concentrations (1-7%), results in the tumour stem cell signature genes being overexpressed 
and also enhances the stem-cell like phenotype of the expanded GBM cells (McCord et al., 
2009; Seidel et al., 2010). Additionally, Pistollato et al. (2009), cultured Grade III and IV 
(GBM)-derived precursor cells (referred to as high-grade gliomas - HGG) which proliferated 
to a higher extent in a hypoxic environment (Pistollato et al., 2009). In their study, they 
compared the expansion of these HGG cells at 2%, 5% and 20% O2 tension and found that 
HGG cell expansion was significantly higher at 2% and 5% O2 tension than at 20% O2 tension 
(Pistollato et al., 2009). At these lower oxygen tensions, there was also a selective suppression 
of mitotic arrest and apoptosis. Also, at these low oxygen tensions, HIF1α expression 
repressed BMP signalling (BMP under high oxygen tension promotes differentiation) thereby 
conferring resistance to differentiation and death (Pistollato et al., 2009). In using in vitro 
expanded GBM-CSCs for the development of novel oncolytic therapeutics it will be necessary 
to be able to control the tumour microenvironment in vitro within set limits. The use of a 
large-scale bioprocess with control capabilities, which is also able to effectively control 
oxygen levels in vitro, will aid in generating clinically-relevant numbers of GBM-CSCs.  
6.2 Large-scale production of hGBM-derived CSC tissue in computer-controlled 
suspension bioreactors 
6.2.1 Scale-up using suspension bioreactors 
In order to generate a large-number of clinically-relevant CSCs, it is necessary to scale-up 
our current process to larger volume bioreactors. Large volume bioreactors have been 
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developed and used for the last 50 years for the culture of different organisms such as 
bacteria, yeast and mammalian cells for pharmaceutical applications (Eibl, 2009). These 
applications include protein production [i.e. production of tissue plasminogen activator 
(tPA) and recombinant erythropoietin (rEPO)] and viral vaccine production (i.e. Hepatitis A 
vaccine) from recombinant cells (Demain & Vaishnav, 2009). However, in comparison to the 
more robust cells currently used in industry, stem cells are fragile and are metabolically 
slower. Therefore, in order to scale-up production of stem/progenitor cells (or in our case 
CSC tissue), it is necessary to consider key variables which may have a more significant 
affect when moving from smaller volumes to larger volumes. Two of these key variables are 
(1) oxygen supply, and (2) hydrodynamic shear in the liquid medium.  
The specific oxygen consumption rates of mammalian cells have been reported to be 
between 1.7x10-17 and 17x10-17 mol O2/cells (Butler, 2004). In our laboratory, we have 
found that single cell suspensions of hNPCs and GBM-derived CSC tissue have specific 
oxygen consumption rates are 5.87x10-17 and 2.99x10-17 mol O2/cells respectively 
(Baghbaderani et al., 2008). Typically for small bioreactors (less than 1.0 L) the oxygen 
demands of cells can be satisfied by gas diffusion from the headspace through the culture 
surface. However, this may not be adequate in larger bioreactors. As the working volume of 
the bioreactor increases, the surface area-to-volume (SAV) ratio (also referred to as the 
aspect ratio) decreases. If we were to consider that we have two bioreactors, one 125 mL and 
one 500 mL, the SAV ratio would decrease from 33.0 m-1 to 15.6 m-1. Therefore, as we scale-
up to larger volume bioreactors, the area available for oxygen transfer through the 
interfacial surface of the medium within the bioreactor, decreases. There are three 
parameters which could be modified in order to maintain adequate oxygen supply in order 
to meet the oxygen demands of the expanding cells (1) sparging oxygen into the culture, (2) 
increasing the agitation rate of the impeller, or (3) increasing the oxygen concentration in the 
headspace. Spargers have been implemented in bacterial fermentation, where high cell 
densities require high oxygen supply. However, since sparging is associated with the 
production of gas bubbles that can burst at the surface of the culture, it can cause cell 
damage which is not recommended for the cultivation of stem cells (Shuler & Kargi, 2002). 
Increasing the agitation rate is another option, since this would increase the dissolution of 
oxygen into the medium. However, as the agitation rate increases, the hydrodynamic shear 
increases which could be detrimental if it causes excessive cell damage. Increasing the 
oxygen concentration in the headspace is also a viable option for small bioreactors, however, 
this may not be sufficient to maintain adequate oxygen supply as the vessel volume 
increases. Thus far, we have evaluated the use of 500 mL bioreactors for the expansion of 
GBM-derived CSC tissue. From our work we have found that increasing the oxygen level in 
the headspace has been sufficient to maintain adequate oxygen supply within our bioreactor 
cultures.  
Hydrodynamic shear is an important characteristic in the culture of cells. The Kolmogoroff 
theory of turbulent eddies (Cherry & Kwon, 1990) and the Nagata correlation (Nagata, 1975) 
can be used to determine the agitation rate to scale-up the cultures. 
6.2.2 Process control 
In order to have a reproducible supply of CSCs in a bioreactor culture process, it is 
necessary to control key culture process parameters within a strict limit. These parameters 
are typically temperature, dissolved oxygen concentration and pH. In order to control these 
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process variables (PV) we use standard process control techniques. Typically, the PV is 
measured by a sensor or probe that is connected to a computer control system (controller) 
[Figure 6]. The controller receives the measurement from the probe, called the control 
variable (CV), and compares it with a predetermined set point (SP) value (this difference is 
called the error or offset (є)). If there is no difference between the CV and SP (є=0), then the 
controller does not take any action. However, if there is a difference between the CV and the 
SP (є≠0), then the controller initiates a corrective feedback in order to shift the process to the 
SP. The controller output is applied through a final control element (FCE) which 
manipulates the input values into the bioreactor in order to apply the corrective feedback 
necessitated by the controller. The manipulated input value is called the manipulated 
variable (MV). The method by which a controller determines the corrective feedback 
necessary is through the combination of proportional, integral and derivative control. 
Proportional control (P-only) is the simplest control strategy. The controller output to the 
FCE is proportional to the error (є) and is given by the equation: 
 MV = Kcє + bias  (3) 
where Kc is the controller gain which is the ratio of the change in the controller output to the 
change in the error. The bias term is the output of the controller when the error is zero. 
There are a few shortcomings of using just a proportional control including its relatively 
slow response to a disturbance in a system, and often the system does not reach the 
predetermined SP.  
Integral controllers (I-only) are used to minimize the error by continually changing the FCE. 





= ∫єdt + bias (4) 
where Ti is the integral time constant. However, the integral controller by itself has a 
response period that is grossly larger than the response period of the proportional 
controller. Typically, integral control is combined with proportional control (PI) which has a 
response period that is 1.5 times the response period of the P-only controller. The equation 




MV K є єdt
T
⎛ ⎞= +⎜ ⎟⎝ ⎠∫  (5) 
A PI controller provides better dynamic control than either a P-only or I-only controller. One 
disadvantage of a PI controller is that a sustaining error could cause the integral term to 
increase and saturate the controller output (known as reset windup) (Seborg, 2011). 
Derivative (D-only) controllers anticipate the behaviour of a process by calculating the rate 






=  (6) 
Where Td is the derivative time constant. Using derivative time decreases lags in the process 
response. In combination with the PI controller we obtain a PID controller which would 
have a response similar to P-only control. The overall process control equation is:  
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The growth and proliferation of hGBM-derived CSC tissue was therefore investigated in 














Fig. 6. A schematic diagram of a process control system for controlling pH, temperature (T) 
and dissolved oxygen (DO2) within a suspension bioreactor system. Using pH control as an 
example: the pH probe measures the pH and transmits a signal carrying that pH value (CV) 
to the controller where it is compared with a pre-determined SP value. The deviation between 
the CV and SP is sent to the control equation, where if there is a deviation present, a corrective 
feedback is provided to the FCE to shift the culture PV to the SP. For example, if the controller 
recognizes that there is a pH increase in the medium, it will output a corrective feedback 
(MV) to the FCE, which in this case increases the CO2 flow to the headspace, which in turn 
decreases the pH of the culture 
6.2.3 Proliferation of hGBM-derived CSC tissue in computer-controlled suspension 
bioreactors 
We inoculated two 500 mL computer-controlled suspension bioreactors at a density of 5.0x104 
cells/mL in PPRF-h2 medium operating in batch mode. Using the Kolmogoroff theory of 
turbulent eddies (Cherry & Kwon, 1990) and the Nagata correlation (Nagata, 1975) we 
determined that an agitation rate of 85 rpm would provide the same maximum shear as 
experienced by a 125 mL suspension bioreactor operating at 100 rpm. Our computer-
controlled suspension bioreactor setup is illustrated in Figure 7. We controlled the dissolved 
oxygen concentration at 70% air saturation (15% atmospheric oxygen concentration), the pH at 
7.4 and the temperature of the vessel at 37°C. Throughout the culture period we observed that 
the growth kinetics of hGBM-derived CSC tissue grown in the computer-controlled 
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suspension bioreactors were similar to hGBM-derived CSC tissue expanded in 125 mL 
suspension bioreactors operated in an incubator maintained at 5% CO2 and 37°C. After 450 
hours in culture, the hGBM-derived CSC tissue attained a maximum viable cell density of 
1.12x106 and 1.26x106 cells/mL in the 125 mL and 500 mL bioreactors, respectively. 
Neurospheres generated in the 500 mL bioreactors had similar morphologies with the 
neurospheres expanded in the 125 mL bioreactors. However, we saw that the neurosphere size 
distribution in the 500 mL bioreactors had an observable shift towards larger neurosphere 
diameters and hypothesized that scaling-up our bioreactor process using maximum shear, 
would allow us to generate similar sized neurospheres in the 500 mL and 125 mL bioreactors. 
However, our observations here suggest that maximum shear may not be the only factor 
impacting neurosphere size within our bioreactors. Additionally, we found that oxygen 
supply through the headspace was sufficient in order to meet the oxygen demands of the cells. 
Further analysis of their differentiation characteristics and CD133 expression, showed that 
these cells retained similar phenotypic characteristics as neurospheres expanded in the 125 mL 
suspension bioreactors. The conclusion of this study was that a computer-controlled 
suspension bioreactor process would be amenable for the large-scale expansion of clinically-
relevant numbers of GBM-derived CSC tissue. Through the use of a computer-controlled 
suspension bioreactor process, we can control key bioprocess parameters in order to generate 
high numbers of GBM-CSCs for the development of novel oncolytic therapeutics. 
 
 
Fig. 7. Photographs of 500 mL DASGIP computer-controlled suspension bioreactors.  
(A) Experimental setup for the 500 mL suspension bioreactor system showing: (1) 500 mL 
suspension bioreactor, (2) temperature and agitation module TC4SC4, (3) gas mixing station 
MX 4/4, (4) multipump modules MP8, (5) DASGIP control and data acquisition computer, 
and (6) DASGIP sensor module PH8PO8. (B) A closer view of the 500 mL DASGIP suspension 
bioreactor, showing: (7) gas inlet to the bioreactor connected to O2, N2, CO2 and air gas 
cylinders via gas mixing station MX 4/4, (8) pH probe, (9) gas outlet from bioreactor,  
(10) heating jacket, (11) stirring plate, (12) dissolved O2 probe, (13) temperature probe and, 
(14) bioreactor sampling port 
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7. Conclusion and perspective 
The highly aggressive brain cancer, hGBM, is thought to arise from a sparse population of 
cells within these tumours, with stem cell-like characteristics, called CSCs. Hence, the 
development of effective cancer therapies may rely on developing methods that specifically 
target these cells. However, the scarcity of CSCs in vivo represents a major impediment to 
such research, as there is an insufficient supply for basic biochemical and genetic analyses. It 
is therefore necessary to develop a bioprocess to expand CSCs in vitro in a controlled 
environment. Our objective was to produce a large amount of hGBM-derived brain CSC 
tissue in computer-controlled suspension bioreactors in order to facilitate the development 
of novel oncolytic therapeutics. In this chapter we focused on two areas of our research: - (1) 
the development of a culture medium to successfully grow the GBM-derived CSC tissue 
and, (2) the development of bioprocess conditions to grow GBM-derived CSC tissue in 
computer-controlled suspension culture. We employed successfully a serum-free medium 
(PPRF-h2), developed in our laboratory (Baghbaderani et al., 2010) for the expansion of 
human neural precursor cells to expand GBM-derived CSC tissue. Using this medium we 
were able to isolate and support the expansion of GBM-derived CSC tissue from primary 
tumours (Panchalingam et al., 2010). We also investigated a number of key bioengineering 
parameters on the expansion of GBM-derived CSC tissue within well-mixed suspension 
bioreactors. Through the refinement of these bioprocess parameters, we successfully 
expanded GBM-derived CSC tissue to large cell numbers in suspension bioreactors, while 
showing that this expanded GBM-derived tissue retained similar genomic characteristics to 
the initial cell population (Panchalingam et al., 2010). The bioreactor protocols we developed 
were applied to the expansion of hGBM-derived CSC tissue in computer-controlled 
suspension bioreactors, which we have shown are able to control our process within very 
strict limits. The use of a computer-controlled bioreactor process to expand hGBM-derived 
CSC tissue can play an important role in the development of novel drug treatments by 
ensuring a continuous homogenous supply of tissue for genomic analysis and high-
throughput drug screening. 
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